Rapport Therapeutics Inc
RAPPHealthcare|Biotechnology|USA
$41.79
-0.25 (-0.60%)
Tangible Book
$9.86
Financials
Financial Snapshot
Market Cap
$2.00B
Enterprise Value
$466.0M
Revenue (TTM)
$20.0M
Net Income (TTM)
$-107.3M
Cash & Equivalents
—
Net Cash/Share
$9.43
Free Cash Flow (TTM)
$-80.7M
Operating CF (TTM)
$-80.3M
Debt/Equity
0.02
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$20.1M
Monthly Burn
$6.7M
Est. Runway
—
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Investments | $31.2M | $147.5M | $305.3M | $490.5M | $476.8M | |
| Operating Cash Flow | $0.00 | $-27.2M | $-64.8M | $-87.5M | $-80.3M | |
| Free Cash Flow | $0.00 | $-28.8M | $-67.2M | $-88.1M | $-80.7M | |
| Capital Expenditure | $0.00 | $-1.6M | $-2.4M | $-616.0K | $-411.0K | |
| Financing Cash Flow | $0.00 | $145.1M | $221.6M | $270.8M | $271.3M |
R&D Spending
R&D (TTM)
$107.9M
R&D Intensity
539.7%
R&D Growth YoY
+13.9%
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $20.0M | |
| R&D Expense | $0.00 | $28.0M | $60.9M | $94.8M | $107.9M | |
| R&D % of Revenue | — | — | — | — | 539.7% | |
| SG&A | $0.00 | $8.2M | $22.1M | $30.3M | $34.3M |
Income Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $20.0M | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $20.0M | |
| R&D | $0.00 | $28.0M | $60.9M | $94.8M | $107.9M | |
| SG&A | $0.00 | $8.2M | $22.1M | $30.3M | $34.3M | |
| Operating Income | $0.00 | $-36.2M | $-83.1M | $-125.1M | $-122.2M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $0.00 | $-34.8M | $-78.3M | $-111.5M | $-107.3M | |
| Net Income | $0.00 | $-34.8M | $-78.3M | $-111.5M | $-107.3M | |
| EPS (Diluted) | 0.00 | -23.10 | -3.78 | -2.86 | -2.60 | |
| EBITDA | $0.00 | $-36.1M | $-82.2M | $-124.1M | $-121.2M | |
| Shares Out. (M) | - | 1.51 | 20.74 | 38.94 | 47.24 |
Balance Sheet
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $31.2M | $70.2M | $56.8M | $52.6M | $78.1M | |
| Marketable Securities | $0.00 | $77.3M | $248.5M | $437.9M | $398.7M | |
| Total Current Assets | $31.3M | $150.9M | $309.8M | $498.6M | $484.7M | |
| Total Assets | $31.6M | $155.4M | $314.9M | $512.4M | $497.6M | |
| Total Current Liabilities | $1.7M | $8.8M | $8.8M | $19.0M | $17.9M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $41.7M | $181.1M | $9.5M | $27.8M | $26.1M | |
| Stockholders' Equity | $-10.1M | $-25.6M | $305.4M | $484.7M | $471.5M | |
| Retained Earnings | $-10.7M | $-45.4M | $-123.7M | $-235.2M | $-255.1M |
Cash Flow Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $0.00 | $-27.2M | $-64.8M | $-87.5M | $-80.3M | |
| Capital Expenditure | $0.00 | $-1.6M | $-2.4M | $-616.0K | $-411.0K | |
| Free Cash Flow | $0.00 | $-28.8M | $-67.2M | $-88.1M | $-80.7M | |
| Investing Cash Flow | $0.00 | $-78.9M | $-170.1M | $-187.5M | $-170.6M | |
| Financing Cash Flow | $0.00 | $145.1M | $221.6M | $270.8M | $271.3M | |
| Issuance of Stock | $0.00 | $54.0K | $157.7M | $269.4M | $269.4M | |
| Repurchase of Stock | $0.00 | $-4.0K | $0.00 | $-1.0K | $-5.0K | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $3.5M | $10.2M | $18.9M | $21.8M | |
| Net Change in Cash | $0.00 | $39.1M | $-13.3M | $-4.2M | $20.5M |
Dilution Tracker
Shares Outstanding
47M
5-Year Share Growth
—
Stock Issuance (TTM)
$269.4M
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Shares Out. (M) | - | 1.51 | 20.74 | 38.94 | 47.24 | |
| YoY Change % | — | — | 1277.0% | 87.7% | 21.3% | |
| Stock Issuance | $0.00 | $54.0K | $157.7M | $269.4M | $269.4M | |
| Stock Repurchase | $0.00 | $-4.0K | $0.00 | $-1.0K | $-5.0K | |
| Stock Based Comp. | $0.00 | $3.5M | $10.2M | $18.9M | $21.8M |
Margins & Profitability
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | -611.0% | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | -536.4% | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | -606.0% | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | -403.5% | |
| ROE % | 0.0% | 0.0% | -56.0% | -28.2% | -26.6% | |
| ROA % | 0.0% | -37.2% | -33.3% | -26.9% | -25.1% | |
| R&D / Revenue | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S98.79
Historical79.39 / 89.17 / 98.79
Industry Med.9.49
P/B4.24
Historical3.40 / 3.82 / 4.24
Industry Med.2.93
EV/EBITDA-12.65
Historical-12.65 / -10.86 / -9.24
Industry Med.13.02
EV/Revenue76.64
Historical56.01 / 65.79 / 76.64
Industry Med.8.59
P/FCF—
Historical— / — / —
Industry Med.27.13
Intrinsic Value Models
Tangible Book
$9.86
Net Current Assets
$9.590
Net-Net Working Capital
$9.43
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| PE Ratio | N/A | N/A | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | - | 98.79 | |
| PB Ratio | 0.00 | 0.00 | 2.12 | 2.99 | 4.24 | |
| EV/EBITDA | 0.00 | 0.00 | -4.20 | -7.82 | -12.65 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 76.64 |
Analyst Estimates & Quality
Altman Z-Score
45.71
Safe
Piotroski F-Score
5
Moderate
Beneish M-Score
—
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $20.00M | $0.00M | $0.00M |
| Net Income | $-166.28M | $-225.46M | $-271.63M |
| EPS | -3.46 | -4.28 | -4.59 |
| Book Value per Share | 7.23 | 0.00 | 0.00 |
| Operating Cash Flow per Share | 0.00 | 0.00 | 0.00 |
| Operating CF | $0.00M | $0.00M | $0.00M |